| pubmed-article:17668342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0038586 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0524637 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:17668342 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:17668342 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:17668342 | pubmed:dateCreated | 2007-8-1 | lld:pubmed |
| pubmed-article:17668342 | pubmed:abstractText | This study examines the association between depressive symptomatology and return to substance use among a sample of 126 veterans consecutively admitted to treatment at a VA intensive outpatient program for substance use disorders. Controlling for numerous demographic and health-related covariates, depressive symptomatology measured at treatment exit with a Beck Depression Inventory (BDI) was significantly predictive of substance use at three-months post-treatment (p < .05). Analysis with a recoded BDI showed that the moderately-to-severely symptomatic (BDI = 20+) were 4.1 times more likely to have returned to substance use than those with a BDI score of under 20. | lld:pubmed |
| pubmed-article:17668342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17668342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17668342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17668342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17668342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17668342 | pubmed:issn | 0095-2990 | lld:pubmed |
| pubmed-article:17668342 | pubmed:author | pubmed-author:BoothB MBM | lld:pubmed |
| pubmed-article:17668342 | pubmed:author | pubmed-author:KirchnerJ EJE | lld:pubmed |
| pubmed-article:17668342 | pubmed:author | pubmed-author:CurranG MGM | lld:pubmed |
| pubmed-article:17668342 | pubmed:author | pubmed-author:DenekeD EDE | lld:pubmed |
| pubmed-article:17668342 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17668342 | pubmed:volume | 33 | lld:pubmed |
| pubmed-article:17668342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17668342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17668342 | pubmed:pagination | 563-9 | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:meshHeading | pubmed-meshheading:17668342... | lld:pubmed |
| pubmed-article:17668342 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17668342 | pubmed:articleTitle | Recognition and management of depression in a substance use disorder treatment population. | lld:pubmed |
| pubmed-article:17668342 | pubmed:affiliation | VA HSR&D Center for Mental Healthcare and Outcome Research, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas 72114, USA. currangeoffrevm@uams.edu | lld:pubmed |
| pubmed-article:17668342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17668342 | pubmed:publicationType | Comparative Study | lld:pubmed |
